Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously pe...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2017-06-01
Sarja:	Blood Advances
Linkit:	http://www.sciencedirect.com/science/article/pii/S2473952920302056
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!